Un-audited Standalone Financial Results of the Company along with the auditor''s Limited Review Report for the Half Year ended as on September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare, currently under Corporate Insolvency Resolution Process (CIRP) since June 2024, filed its half-year results for September 30, 2025 signed by the Resolution Professional. Revenue from operations fell sharply to ₹1,132.17 lakhs from ₹1,854.68 lakhs in the same period last year, a drop of about 39%. The company reported a net loss of ₹418.87 lakhs, better than the ₹1,552.01 lakhs loss a year ago, but still deep in the red. Cash from operations turned sharply negative at ₹(710.53) lakhs versus ₹492.87 lakhs last year, and current liabilities (₹9,427.95 lakhs) far exceed current assets (₹6,100.85 lakhs). The wholly owned subsidiary Dr. Smiths Biotech is also under CIRP, so consolidated results could not be finalized. The auditor issued a Disclaimer of Conclusion, highlighting multiple uncertainties including going concern, pending NCLT approval of the resolution plan, unreconciled inventory values, delayed statutory dues, and GST reconciliation gaps.
Shareholders face very high uncertainty — the company is under insolvency proceedings, results carry a disclaimer rather than a clean opinion, and the NCLT order on the resolution plan is awaited which will decide the fate of equity holders. Stock is likely to remain highly volatile and speculative.